端粒酶逆转录酶
甲状腺癌
甲状腺癌
医学
甲状腺乳突癌
端粒酶
甲状腺
突变
内科学
癌症
甲状腺切除术
癌
肿瘤科
胃肠病学
癌症研究
病理
基因
生物
遗传学
作者
Christina Laschinsky,Sarah Theurer,Thomas Herold,Josefine Rawitzer,Frank Weber,Ken Herrmann,Tim Brandenburg,Dagmar Führer‐Sakel,Wolfgang P. Fendler,Manuel Weber
标识
DOI:10.2967/jnumed.123.266044
摘要
The onset of radioiodine-refractory thyroid carcinoma (RR-TC) is a negative predictor of survival and has been linked to the presence of BRAFV600E mutations in papillary thyroid cancer. We aimed to identify further genetic alterations associated with RR-TC. Methods: We included 38 patients with papillary thyroid cancer who underwent radioiodine imaging and 18F-FDG PET/CT after total thyroidectomy. The molecular profile was assessed by next-generation sequencing. The time to the onset of RR-TC for different genetic alterations was compared using the log-rank test. Results: The median onset to RR-TC was 0.7 and 19.8 mo in patients with and without, respectively, telomerase reverse transcriptase promoter mutations (P = 0.02) and 1.7 and 19.8 mo in patients with and without, respectively, a tumor protein 53 mutation (P < 0.01). This association was not observed for BRAFV600E mutations (P = 0.49). Conclusion: Our data show a significant association between the onset of RR-TC and mutations in telomerase reverse transcriptase promoter and tumor protein 53, indicating the need for a more extensive diagnostic workup in these patients. Certain genetic changes put patients with thyroid cancer at risk of developing cancer spread that does not respond to radioiodine therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI